CJC-1295 references and citations

The CJC-1295 references behind this digest

The CJC-1295 references below are the complete source set for this digest. The core human pharmacokinetics rest on Teichman 2006 and Ionescu/Frohman 2006 ^[1][3]; the molecular and animal foundation on Jette 2005 and Alba 2006 ^[2][4]; the regulatory and anti-doping context on the 2024 FDA PCAC review and Henninge 2010 ^[1][6]; and the class-level framing on the 2025 Nature Reviews Endocrinology review ^[13]. Each numbered entry corresponds to the inline markers used across the human and animal research and the other pages.

The register is deliberately mixed by evidence type. Entries 1 and 3 are the foundational human pharmacokinetic studies — the measured telemetry the whole site is built around. Entries 2, 4, and 5 are the animal and mechanistic work that explains how the long-acting design produces those kinetics. Entry 6 is the analytical-chemistry identification of CJC-1295 in a seized preparation, and entry 7 is the discontinued ConjuChem Phase 2 registry record. Entries 12, 13, 14, and 16 supply the GH-physiology and class-level context — fluid retention, the GHRH-analog landscape, adult GH-deficiency guidance, and the unapproved-peptide safety review. Where a source disagrees with another on a chemical identifier, this digest flags the uncertainty in the body rather than resolving it silently.